Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Safety and efficacy of a new high‐dose regimen of panobinostat, gemcitabine, busulfan, and melphalan for 1st or 2nd salvage ASCT for refractory/relapsed or high‐risk myeloma: Matched‐pair comparisons with concurrent control cohorts

American Journal of Hematology(2023)10.1002/ajh.27168Source: DataRank Database

Safety and efficacy of a new high‐dose regimen of panobinostat, gemcitabine, busulfan, and melphalan for 1st or 2nd salvage ASCT for refractory/relapsed or high‐risk myeloma: Matched‐pair comparisons with concurrent control cohorts is a research paper published in American Journal of Hematology (2023). On theSindex it has a DataRank of 0.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access0 citations

Download PDF

Cite:

Linked data & code

nct

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (2 grants)Impact (FWCI 0.00)OA: bronzeTopics (23)IDs (PubMed, PMC, OpenAlex)Annotations (1)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (8)

Zixi Yang,Benigno C. Valdez ORCID,Suprateek Kundu ORCID,Qaiser Bashir ORCID,Jeremy Ramdial ORCID

Live enrichment

PubMed:38100199 PMC:PMC11849400 OpenAlex:https://openalex.org/W4389779286

National Institutes of Health

Grant: P30 CA016672

Novartis

FWCI

0.00

Citation Percentile

0.5%

bronzeLicense: http://onlinelibrary.wiley.com/termsAndConditions#vor

journalhttps://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/ajh.27168

publisherhttps://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/ajh.27168

publisherhttps://onlinelibrary.wiley.com/doi/pdf/10.1002/ajh.27168

journalhttp://dx.doi.org/10.1002/ajh.27168

repositoryhttps://pubmed.ncbi.nlm.nih.gov/38100199

Fields of Study

Multiple Myeloma Research and TreatmentsProtein Degradation and InhibitorsHistone Deacetylase Inhibitors Research

MeSH Terms

PanobinostatGemcitabineAntineoplastic Combined Chemotherapy ProtocolsBusulfanHumansMelphalanMultiple MyelomaTransplantation, AutologousHematopoietic Stem Cell Transplantation

Keywords

MedicineMelphalanAutologous stem-cell transplantationInternal medicinePanobinostatOncologyBusulfanMultiple myelomaSurgeryHematopoietic stem cell transplantationTransplantation

Sustainable Development Goals

SDG 0: Good health and well-being